SCHEMBL4882914

SCHEMBL4882914

CC(C)c1ccc(NS(=O)(=O)c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.61
MAPT P10636 3/20 0.60
LMNA P02545 2/20 0.60
MEN1 O00255 1/20 0.60
ALOX12 P18054 1/20 0.60
KMT2A Q03164 1/20 0.60
NLRP1 Q9C000 1/20 0.60
ITGA1 P56199 4/20 0.59
IDH1 O75874 1/20 0.56
HDAC1 Q13547 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
PPARG P37231 4/20 0.54
ALDH1A1 P00352 2/20 0.52
HTT P42858 2/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CDK1 P06493 1/20 0.50
CCNB1 P14635 1/20 0.50
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28121241 0.84 MAPT (0.63) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL14018772 0.84 MAPT (0.63) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL94831 0.81 MAPT (0.63) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL7577795 0.81 ITGA1 (0.74) PGRMAPTLMNAMEN1ALOX12
SCHEMBL4880800 0.81 MAPT (0.79) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL14018763 0.80 ALDH1A1 (0.82) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL3268657 0.80 MAPT (0.61) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL3267463 0.79 HDAC1 (0.66) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL16325537 0.79 CDK1 (0.65) MAPTLMNAMEN1ALOX12KMT2A
SCHEMBL4875550 0.79 MAPT (0.48) MAPTLMNAMEN1ALOX12KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255169-A1 4'-Fluoro-biphenyl-3-sulfonic acid benzo[1,3]dioxol-5-ylamide, for example; for use as an alpha 2 beta 1 integrin I domain inhibitor; use as a medicament for treating thrombosis and cancer spread NR1I2, ITGA2, ITGB2 PGR 421/4885MAPT 4739/4885LMNA 3369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.